DRUG DEVELOPMENT AND EVALUATION: AGE, SEX, AND FRAILTY CONSIDERATIONS TO FACILITATE THE FORTITUDE FACTOR
Sarah Hilmer · 2024
Read DRUG DEVELOPMENT AND EVALUATION: AGE, SEX, AND FRAILTY CONSIDERATIONS TO FACILITATE THE FORTITUDE FACTOR by Sarah Hilmer (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11690999.txt.
Description
Sarah Hilmer argues that drug testing must weigh age, sex, and frailty together, in work from 2024. Older adults respond to drugs in varied ways that trials often miss. Kidney clearing, body reserve, and drug sensitivity all shift with these three factors.
Sometimes the factors push the same way, as when age, female sex, and frailty each slow drug clearing. At other times they pull apart, which makes net effects hard to predict. Other drugs, other diseases, genes, and life exposures add more layers. A global pharmacology group's statement on frailty measurement anchors the piece. Hilmer urges trial designs that measure frailty from the start.
Catalog record
| CREATOR | Sarah Hilmer |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |